
CLAIMS

What is claimed is:

1. Use of a compound in the manufacture of a medicament for the treatment of pancreatic cancer in a subject,

wherein the ~~A method of treating pancreatic cancer, the method comprising administering to a subject in need thereof an effective amount of a~~ compound is represented by the following structural formula:



;

or a pharmaceutically acceptable salt thereof, wherein:

the thiazole ring is optionally substituted with –F or –Cl;

Cy is -(C_3–C_7)cycloalkyl, bridged (C_6–C_{12}) cycloalkyl, or a 4-10 membered heterocyclic ring, each of which is optionally substituted with one or more groups selected from the group consisting of halogen, -OH, (C_1-C_4)alkyl, and (C_1-C_4)alkoxy;

when X^5 is connected with a nitrogen ring atom of Cy, X^5 is absent;

when X^5 is connected with a carbon ring atom of Cy, X^5 is NR^a or O;

X^6 is NR^a or O;

R^1 is (C_1–C_5)alkyl optionally substituted with -OH;

R^3 is (C_1–C_5)alkyl, -CH_2-phenyl, -(C_3–C_7)cycloalkyl, -CH_2-(C_3–C_7)cycloalkyl, -CH_2-monocyclic 3-7 membered heterocyclic ring, or monocyclic 3-7 membered heterocyclic ring, wherein the (C_1–C_5)alkyl, -(C_3–C_7)cycloalkyl, phenyl or monocyclic 3-7 membered heterocyclic ring represented by R^3 or in the group represented by R^3 is optionally substituted with one or more groups selected from the group consisting of halogen, -OH, (C_1-C_4)alkyl, halomethyl, halomethoxy, -CN, and (C_1-C_4)alkoxy;

R^2 is -$NR^aC(O)O$(C_1-C_4)alkyl; -$NR^aC(O)NR^a$(C_1-C_4)alkyl; -$NR^aC(O)O$(C_2-C_4)alkenyl; -$NR^aC(O)NR^a$(C_2-C_4)alkenyl; -$NR^aC(O)O$-(C_3-C_6)cycloalkyl; -$NR^aC(O)NR^a$-(C_3-C_7)cycloalkyl; -$NR^aC(O)O$-phenyl; -$NR^aC(O)NR^a$-phenyl; -$NR^aC(O)O$-monocyclic 3-7 membered heterocyclic ring; -$NR^aC(O)NR^a$-monocyclic 3-7 membered heterocyclic ring; -$NR^aC(O)O$-monocyclic 5-6 membered heteroaromatic ring; -$NR^aC(O)NR^a$-monocyclic 5-6 membered heteroaromatic ring;

wherein the (C_1–C_4)alkyl and the (C_2-C_4)alkenyl in the group represented by R^2 are each optionally and independently substituted with one or more groups selected from the group consisting of halogen, N_3, –OR^a, -NR^aR^a, -(C_3–C_6)cycloalkyl, phenyl, a monocyclic 3-7 membered heterocyclic ring, and a monocyclic 5-6 membered heteroaromatic ring;

wherein the (C_3–C_7)cycloalkyl in the group represented by R^2 is optionally substituted with one or more groups selected from the group consisting of halogen, -CH_3, =O, -OR^a and -NR^aR^a;

wherein the phenyl in the group represented by R^2 is optionally substituted with one or more groups selected from the group consisting of halogen, -CH_3, halomethyl, halomethoxy, -CN, -OR^a, and -N_3;


wherein the heterocyclic ring in the group represented by R^2 is optionally substituted with one or more groups selected from the group consisting of =O, halogen, –OR^a, -CH_3, halomethyl, and halomethoxy;

wherein the heteroaromatic ring in the group represented by R^2 is optionally substituted with one or more groups selected from the group consisting of halogen, -CN, -CH_3, halomethyl, halomethoxy, -OR^a and -NR^aR^a; and

each R^a is independently –H or -CH_3.

2. Use of a compound in the manufacture of a medicament for the ~~A method of~~ treatmen~~ting~~ of pancreatic cancer in a subject,

wherein the ~~method comprising administering to a subject in need thereof an effective amount of a~~ compound is represented by the following structural formula:



;

or a pharmaceutically acceptable salt thereof, wherein:

the thiazole ring is optionally substituted with -F or –Cl;

Cy is cyclohexyl or a 6-membered monocyclic heterocyclic ring;

X^5 and X^6 are each independently NR^a or O;

R^1 is (C_1–C_5)alkyl;

R^3 is (C_1–C_5)alkyl or monocyclic 3-7-membered heterocyclic ring;

R^2 is -$NR^aC(O)O(C_1$-$C_4)$alkyl; -$NR^aC(O)NR^a(C_1$-$C_4)$alkyl; -$NR^aC(O)O(C_2$-$C_4)$alkenyl; -$NR^aC(O)NR^a(C_2$-$C_4)$alkenyl; -$NR^aC(O)$-$O(C_3$-$C_6)$cycloalkyl; -$NR^aC(O)NR^a$-$(C_3$-$C_6)$cycloalkyl; -$NR^aC(O)O$-phenyl; -$NR^aC(O)NR^a$-phenyl; -$NR^aC(O)O$-monocyclic 3-7 membered heterocyclic ring; -$NR^aC(O)NR^a$-monocyclic 3-7 membered heterocyclic ring; -$NR^aC(O)O$-monocyclic 5-6 membered heteroaromatic ring; -$NR^aC(O)NR^a$-monocyclic 5-6 membered heteroaromatic ring;

wherein the $(C_1–C_4)$alkyl and the $(C_2$-$C_4)$alkenyl in the group represented by R^2 are each optionally and independently substituted with one or more halogen, N_3, $–OR^a$, -NR^aR^a, -$(C_3–C_6)$cycloalkyl, phenyl, monocyclic 3–7-membered heterocyclic ring, or monocyclic 5–6-membered heteroaromatic ring;

wherein the -$(C_3–C_6)$cycloalkyl in the group represented by R^2 is optionally substituted with one or more halogen, -CH_3, -OR^a or -NR^aR^a;

wherein the phenyl in the group represented by R^2 is optionally substituted with one or more halogen, -CH_3, halomethyl, halomethoxy, -OR^a, or -N_3;

wherein the heterocyclic ring in the group represented by R^2 is optionally substituted with one or more =O, halogen, -CH_3, halomethyl, or halomethoxy;

wherein the heteroaromatic ring in the group represented by R^2 is optionally substituted with one or more halogen, -CH_3, halomethyl, halomethoxy, -OR^a or -NR^aR^a; and

each R^a is independently –H or -CH_3.

3. The use~~method~~ of claim 1, wherein Cy is

cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl;


azetidinyl, azepanyl, diazaspiro[4.4]nonyl, diazaspiro[3.5]nonyl, diazepanyl, dihydroimidazole, dihydrofuranyl, dihydropyranyl, dihydropyridinyl, dihydropyrimidinyl, dihydrothienyl, dihydrothiophenyl, dihydrothiopyranyl, hexahydropyridazinyl, hexahydropyrimidinyl, hydantoinyl, indolinyl, isoindolinyl, morpholinyl, oxiranyl, oxetanyl, piperidinyl, piperazinyl, pyrrolidinonyl, pyrrolidinyl, tetrahydrofuranyl, tetrahydroimidazole, tetrahydroindolyl, tetrahydropyranyl, tetrahydrothienyl, tetrahydropyridinyl, tetrahydropyrimidinyl, tetrahydrothiophenyl, tetrahydrothiopyranyl, thiomorpholinyl, tropanyl, valerolactamyl;

bicyclo[2.1.1]hexyl, bicyclo[2.2.1]heptyl, bicyclo[2.2.2]octyl, bicyclo[3.2.1]octyl, bicyclo[4.3.1]decyl, bicyclo[3.3.1]nonyl, bornyl, bornenyl, norbornyl, norbornenyl, 6,6-dimethylbicyclo [3.1.1]heptyl, tricyclobutyl, adamantly;

azanorbornyl, quinuclidinyl, isoquinuclidinyl, tropanyl, azabicyclo[2.2.1]heptanyl, 2-azabicyclo[3.2.1]octanyl, azabicyclo[3.2.1]octanyl, azabicyclo[3.2.2]nonanyl, azabicyclo[3.3.0]nonanyl, azabicyclo [3.3.1]nonanyl, diazabicyclo[2.2.1]heptanyl, diazabicyclo[3.2.1]octanyl, octahydropyrrolo[3,4-b]pyrrolyl, octahydropyrrolo[3,4-c]pyrrolyl.

4. The use~~method~~ of any one of claims 1-3, wherein Cy is cyclohexyl, morpholinyl, thiomorpholinyl, piperidinyl, piperazinyl, hexahydropyridazinyl, hexahydropyrimidinyl, valerolactamyl, dihydropyranyl, dihydropyridinyl, dihydropyrimidinyl, dihydrothiopyranyl, tetrahydropyranyl, tetrahydropyridinyl, tetrahydropyrimidinyl, or tetrahydrothiopyranyl.

5. The use~~method~~ of any one of claims 1-4, the medicament~~method~~ comprising ~~administering to a subject in need thereof an effective amount of~~ a compound represented by the following structural formula:



;

or a pharmaceutically acceptable salt thereof, wherein:

X^7 is NH or O;

R^4 is (C_1–C_4)alkyl, (C_3-C_6)cycloalkyl, or a monocyclic 3-7 membered heterocyclic ring;

wherein the (C_1–C_4)alkyl represented by R^4 is optionally substituted with one or more groups selected from the group consisting of halogen, N_3, –OR^a, -NR^aR^a, -(C_3–C_6)cycloalkyl, phenyl, a monocyclic 3-7 membered heterocyclic ring, and a monocyclic 5-6 membered heteroaromatic ring,

wherein the (C_3-C_6)cycloalkyl or the monocyclic 3-7 membered heterocyclic ring represented by R^4, the (C_3-C_6)cycloalkyl or the monocyclic 3-7 membered heterocyclic ring in the group represented by R^4 is optionally substituted with one or more groups selected from the group consisting of halogen, -OR^a, =O, and -CH_3,

wherein the phenyl in the group represented by R^4 is optionally substituted with one or more groups selected from the group consisting of halogen, $-CH_3$, halomethyl, halomethoxy, $-OR^a$, and $-N_3$;

wherein the heteroaromatic ring in the group represented by R^4 is optionally substituted with one or more groups selected from the group consisting of halogen and $-CH_3$.


6. The use~~method~~ of claim 5, wherein

X^7 is NH or O;

R^3 is $(C_1–C_5)$alkyl; and

R^4 is $(C_1–C_4)$alkyl wherein the $(C_1–C_4)$alkyl represented by R^4 is optionally substituted with one or more halogen, $–OR^a$, $-NR^aR^a$, $-(C_3–C_6)$cycloalkyl, phenyl (optionally substituted by one or more halogen, $-CH_3$, halomethyl, halomethoxy, OR^a or N_3), monocyclic 3–7-membered heterocyclic ring (optionally substituted by =O, halogen or $–CH_3$), or monocyclic 5–6-membered heteroaromatic ring (optionally substituted by halogen or $–CH_3$).


7. The use~~method~~ of any one of claims 1-6, the medicament~~method~~ comprising ~~administering to a subject in need thereof an effective amount of~~ a compound represented by the following structural formula:



;

or a pharmaceutically acceptable salt thereof.


8. The use~~method~~ of any one of claims 1-6, the medicament~~method~~ comprising ~~administering to a subject in need thereof an effective amount of~~ a compound represented by the following structural formula:



;

or a pharmaceutically acceptable salt thereof.


9. The use~~method~~ of any one of claims 1-6, the medicament~~method~~ comprising ~~administering to a subject in need thereof an effective amount of~~ a compound represented by the following structural formula:



;

or a pharmaceutically acceptable salt thereof.


10. The use~~method~~ of any one of claims 1-6, the medicament~~method~~ comprising ~~administering to a subject in need thereof an effective amount of~~ a compound represented by the following structural formula:



;

or a pharmaceutically acceptable salt thereof.


11. The use~~method~~ of any one of claims 1-6, the medicament~~method~~ comprising ~~administering to a subject in need thereof an effective amount of~~ a compound represented by the following structural formula:



;

or a pharmaceutically acceptable salt thereof.

12. The use~~method~~ of any one of claims 1-6, the medicament~~method~~ comprising ~~administering to a subject in need thereof an effective amount of~~ a compound represented by the following structural formula:



;

or a pharmaceutically acceptable salt thereof.

13. The use~~method~~ of any one of claims 1-6, wherein Cy is azetidinyl or pyrrolidinyl, and the nitrogen ring atom is connected with the thiazole ring.

14. The use~~method~~ of any one of claims 1-6, wherein Cy is 1,7-diazaspiro[4.4]nonyl, 2,7-diazaspiro[4.4]nonyl, 2,7-diazaspiro[3.5]nonyl, 1,4-diazepanyl, 2,5-diazabicyclo[2.2.1]heptanyl, 3,8-diazabicyclo[3.2.1]octanyl, octahydropyrrolo[3,4-b]pyrrolyl, or octahydropyrrolo[3,4-c]pyrrolyl, and the two nitrogen ring atoms are connected with the thiazole ring and the $-X^5C(O)X^6R^3$ moiety, respectively.

15. The use~~method~~ of any one of claims 5 and 7-14, wherein R^4 is $-(C_1–C_3)$alkyl, (C_3-C_6)cycloalkyl, or a monocyclic 3-7 membered heterocyclic ring, wherein the $-(C_1–C_3)$alkyl is optionally substituted with (i) phenyl optionally substituted by one or more halogen or $-CH_3$; (ii) a monocyclic 5-6 membered heteroaromatic ring optionally substituted by one or more halogen or $–CH_3$; or (iii) a monocyclic 3-7 membered heterocyclic ring optionally substituted by one or more groups selected from the group consisting of halogen and $–CH_3$.

16. The use~~method~~ of any one of claims 5 and 7-14, wherein R^4 is $-(C_1–C_3)$alkyl, $-CHR^a$-phenyl, $-CHR^a$-5–6 membered heteraromatic ring, or $-CHR^a$-3-7 membered monocyclic heterocyclic ring, wherein the phenyl, 5–6 membered heteraromatic ring or 3-7 membered monocyclic heterocyclic ring in the group represented by R^4 is optionally substituted one or more groups selected from the group consisting of halogen and $–CH_3$.


17. The use~~method~~ of any one of claims 5-14, wherein R^4 is $-(C_1–C_3)$alkyl, optionally substituted with (i) phenyl optionally substituted by one or more halogen, $-CH_3$, halomethyl, halomethoxy, OR^a, or N_3; (ii) a monocyclic 5–6-membered heteroaromatic ring optionally substituted by one or more halogen or $-CH_3$; or (iii) a monocyclic 3–7-membered heterocyclic ring optionally substituted by one or more =O or $–CH_3$.

18. The use~~method~~ of claim 17, wherein R^4 is (i) $-(C_1–C_3)$alkyl; (ii) $-CH_2$-phenyl optionally substituted by halogen, $-CH_3$, halomethyl, halomethoxy, OR^a, or N_3; (iii) $–CH(CH_3)$-phenyl optionally substituted by halogen, $-CH_3$, halomethyl, halomethoxy, OR^a, or

N_3; (iv) -CH_2-5–6-membered heteraromatic ring optionally substituted by halogen or –CH_3; or (v) -CH_2-3–7-membered monocyclic heterocyclic ring optionally substituted by =O or –CH_3.

19. The use~~method~~ of any one of claims 1, 3-5, and 7-18, wherein R^3 is (C_1–C_4)alkyl, -(C_4–C_6)cycloalkyl, -CH_2-phenyl, -CH_2-monocyclic 4-6 membered heterocyclic ring, or monocyclic 4-6 membered heterocyclic ring, wherein the phenyl or monocyclic 4-6 membered heterocyclic ring represented by R^3 or in the group represented by R^3 is optionally substituted with one or more groups selected from the group consisting of halogen, -OR^a, and –CH_3.


20. The use~~method~~ of any one of claims 1-7 and 15-19, the medicament~~method~~ comprising ~~administering to a subject in need thereof an effective amount of~~ a compound represented by the following structural formula:



;

or a pharmaceutically acceptable salt thereof.


21. The use~~method~~ of claim 20, the medicament~~method~~ comprising ~~administering to a subject in need thereof an effective amount of~~ a compound represented by the following structural formula:



;

or a pharmaceutically acceptable salt thereof.


22. The use~~method~~ of any one of claims 1-6, 8, and 15-19, the medicament~~method~~ comprising ~~administering to a subject in need thereof an effective amount of~~ a compound represented by the following structural formula:




;

or a pharmaceutically acceptable salt thereof.

23. The use~~method~~ of claim 22, the medicament~~method~~ comprising ~~administering to a subject in need thereof an effective amount of~~ a compound represented by the following structural formula:




, or



;


or a pharmaceutically acceptable salt thereof.

24. The use~~method~~ of any one of claims 1-6, 10, and 15-19, the medicament~~method~~ comprising ~~administering to a subject in need thereof an effective amount of~~ a compound represented by the following structural formula:



;





or a pharmaceutically acceptable salt thereof.



25. The use~~method~~ of any one of claims 1-24, wherein R^3 is isopropyl, *tert*-butyl, cyclobutyl, cyclopentyl, benzyl, oxetanyl, tetrahydro-2H-pyranyl, or .




26. The use~~method~~ of any one of claims 1-25, wherein R^1 is *tert*-butyl.







27. The use~~method~~ of any one of claims 1-26, wherein R^3 is isopropyl or oxetanyl.







28. The use~~method~~ of claim 27, wherein R^3 is isopropyl.



29. The use~~method~~ of any one of claims 5-28, wherein R^4 is , , , , or .

30. The use~~method~~ of claim 29, wherein R^4 is , , or .

31. The use~~method~~ of claim 29, wherein R^4 is , , or .

32. The use~~method~~ of claim 29, wherein R^4 is , , , , , or .

33. The use~~method~~ of claim 29, wherein R^4 is , , , , , or .

34. The ~~method~~ use of claim 29, wherein R^4 is  or .

35. The use~~method~~ of any one of claims 1-34, wherein the medicament further comprise~~sing the step of co-administering to the subject an effective amount of~~ a DNA repair inhibitor, a DNA damage response (DDR) inhibitor, a DNA damaging agent or an immunomodulatory agent; or

wherein the medicament is for administration with a DNA repair inhibitor, a DNA damage response (DDR) inhibitor, a DNA damaging agent or an immunomodulatory agent.

36. The use~~method~~ of claim 35, wherein the DNA damaging agent is selected from the group consisting of: exposure to a DNA damaging chemical; exposure to a chemotherapeutic agent; exposure to a radiochemotherapy, and exposure to ionizing or ultraviolet radiation.

37. The use~~method~~ of any one of claims 35-36, wherein the subject is determined to have an increased level and/or activity of a DNA damage process or DNA editing enzyme.

38. The use~~method~~ of claim 37, wherein the immunomodulatory agent is selected from the group consisting of immune checkpoint modulators, Toll-like receptor (TLR) agonists, cell-based therapies, cytokines and cancer vaccines.

39. The use~~method~~ of claim 37, wherein the DNA editing enzyme is selected from the group consisting of activation induced cytidine deaminase (AID or AICDA), APOBEC2, APOBEC3A, APOBEC3C, APOBEC3D, APOBEC3F, APOBEC3G, APOBEC3H, APOBEC4, a Type 1 Topoisomerase, a Type 2 Topoisomerase, Recombination Activating Gene 1 (RAG 1), and Recombination Activating Gene 2 (RAG2).

40. The use~~method~~ of any one of claims 1-39, wherein the subject is a mammal.

41. The use~~method~~ of any one of claims 1-40, wherein the subject is a human.

42. The use~~method~~ of any one of claims 1-41, wherein the medicament~~RAD51 inhibitor~~ is formulated for administration of the compound~~administered~~ at a dosage ranging from about 1 mg/m^2 to about 500 mg/m^2.

43. The use~~method~~ of any one of claims 1-41, wherein the medicament~~RAD51 inhibitor~~ is formulated for administration of the compound~~administered~~ at a dosage of about 3±2 mg/m^2, 3±1.8 mg/m^2, 3±1.6 mg/m^2, 3±1.5 mg/m^2, 3±1.4 mg/m^2, 3±1.3 mg/m^2, 3±1.2 mg/m^2, 3±1.1 mg/m^2, 3±1 mg/m^2, 3±0.9 mg/m^2, 3±0.8 mg/m^2, 3±0.7 mg/m^2, 3±0.6 mg/m^2, 3±0.5 mg/m^2, 3±0.4 mg/m^2, 3±0.3 mg/m^2, 3±0.2 mg/m^2, or 3±0.1 mg/m^2.

44. The use~~method~~ of any one of claims 1-41, wherein the medicament~~RAD51 inhibitor~~ is formulated for administration of the compound~~administered~~ at a dosage of about 3 mg/m^2.

45. The use~~method~~ of any one of claims 1-41, wherein the medicament~~RAD51 inhibitor~~ is formulated for administration of the compound~~administered~~ at a dosage of about 120±100 mg/m^2, 120±90 mg/m^2, 120±80 mg/m^2, 120±70 mg/m^2, 120±60 mg/m^2, 120±50 mg/m^2, 120±45 mg/m^2, 120±40 mg/m^2, 120±35 mg/m^2, 120±30 mg/m^2, 120±25 mg/m^2, 120±20 mg/m^2, 120±15 mg/m^2, 120±10 mg/m^2, 120±9 mg/m^2, 120±8 mg/m^2, 120±7 mg/m^2, 120±6 mg/m^2, 120±5 mg/m^2, 120±4 mg/m^2, 120±3 mg/m^2, 120±2 mg/m^2, or 120±1 mg/m^2.

46. The use~~method~~ of any one of claims 1-41, wherein the medicament~~RAD51 inhibitor~~ is formulated for administration of the compound~~administered~~ at a dosage of about 120 mg/m^2.

47. The use~~method~~ of any one of claims 1-41, wherein the medicament~~RAD51 inhibitor~~ is formulated for administration of the compound ~~administered~~ at a dosage of about 240±100 mg/m^2, 240±90 mg/m^2, 240±80 mg/m^2, 240±70 mg/m^2, 240±60 mg/m^2, 240±50 mg/m^2, 240±45 mg/m^2, 240±40 mg/m^2, 240±35 mg/m^2, 240±30 mg/m^2, 240±25 mg/m^2, 240±20 mg/m^2, 240±15 mg/m^2, 240±10 mg/m^2, 240±9 mg/m^2, 240±8 mg/m^2, 240±7 mg/m^2, 240±6 mg/m^2, 240±5 mg/m^2, 240±4 mg/m^2, 240±3 mg/m^2, 240±2 mg/m^2, or 240±1 mg/m^2.

48. The use~~method~~ of any one of claims 1-41, wherein the medicament~~RAD51 inhibitor~~ is formulated for administration of the compound ~~administered~~ at a dosage of about 240 mg/m^2.

49. The use~~method~~ of any one of claims 1-41, wherein the medicament~~RAD51 inhibitor~~ is formulated for administration of the compound ~~administered~~ followed by a 14-day dosing holiday.

50. The use~~method~~ of any one of claims 1-41, wherein the medicament~~RAD51 inhibitor~~ is formulated for administration of the compound~~administered~~ followed by a 21-day dosing holiday.

51. The use~~method~~ of any one of claims 1-41, wherein the medicament~~RAD51 inhibitor~~ is formulated for administration of the compound~~administered~~ at about 240 mg/m^2 followed by a 14-day dosing holiday.

52. The use~~method~~ of any one of claims 1-41, wherein the medicament~~RAD51 inhibitor~~ is formulated for administration of the compound~~administered~~ at about 240 mg/m^2 followed by a 21-day dosing holiday.

53. The use~~method~~ of any one of claims 1-41, wherein the medicament~~RAD51 inhibitor~~ is formulated for administration of the compound ~~administered~~ at about 120 mg/m^2 followed by a 14-day dosing holiday.

54. The use~~method~~ of any one of claims 1-41, wherein the medicament~~RAD51 inhibitor~~ is formulated for administration of the compound ~~administered~~ at about 120 mg/m^2 followed by a 21-day dosing holiday.

~~55. The method of any one of claims 1-41, wherein the RAD51 inhibitor is Compound 67A or the pharmaceutically acceptable salt thereof.~~

~~56~~55. The use~~method~~ of any one of claims 1-41, wherein the medicament ~~RAD51 inhibitor~~ is formulated for administration of the compound~~administered~~ at a dosage ranging from about 50 mg/day to about 500 mg/day.


~~57~~56. The use~~method~~ of any one of claims 1-55~~56~~, wherein the medicament~~RAD51 inhibitor~~ is formulated for administration ~~administered~~ once daily.

~~58~~57. The use~~method~~ of any one of claims 1-55~~56~~, wherein the medicament~~RAD51 inhibitor~~ is formulated for administration ~~administered~~ once every other day.

~~59~~58. The use~~method~~ of any one of claims 1-56~~57~~, wherein the medicament~~RAD51 inhibitor~~ is formulated for adminstration~~administered~~ once daily for four weeks.

~~60~~59. The ~~method~~ use of any one of claims 1-56~~57~~, wherein the ~~RAD51 inhibitor~~medicament is formulated for administration~~administered~~ once daily for four weeks followed by a dosing holiday.

~~61~~60. The use~~method~~ of any one of claims 1-59~~60~~, wherein the ~~RAD51 inhibitor~~compound is Compound 67A:



(Compound 67A);

or a pharmaceutically acceptable salt thereof.

~~62. A composition comprising Compound 67A, or a pharmaceutically acceptable salt thereof, for use in treating pancreatic cancer in a subject in need thereof.~~

~~63. Compound 67A, or a pharmaceutically acceptable salt thereof, for use in treating pancreatic cancer in a subject in need thereof.~~

~~64. Use of a composition comprising Compound 67A, or a pharmaceutically acceptable salt thereof, for the treatment of pancreatic cancer in a subject in need thereof.~~

~~65. Use of Compound 67A, or a pharmaceutically acceptable salt thereof, for the treatment of pancreatic cancer in a subject in need thereof.~~

~~66. Use of a composition comprising Compound 67A, or a pharmaceutically acceptable salt thereof, for the manufacture of a medicament for the treatment of pancreatic cancer in a subject in need thereof.~~

~~67. Use of Compound 67A, or a pharmaceutically acceptable salt thereof, for the manufacture of a medicament for the treatment of pancreatic cancer in a subject in need thereof.~~